Your browser doesn't support javascript.
loading
Structure-activity relationship of lipid, cyclic peptide and antigen rearrangement of physically mixed vaccines.
Huang, Wenbin; Madge, Harrison Y R; Zhang, Jiahui; Gilmartin, Lachlan; Hussein, Waleed M; Khalil, Zeinab G; Koirala, Prashamsa; Capon, Robert J; Toth, Istvan; Stephenson, Rachel J.
Afiliación
  • Huang W; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane 4072, Australia.
  • Madge HYR; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane 4072, Australia.
  • Zhang J; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane 4072, Australia.
  • Gilmartin L; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane 4072, Australia.
  • Hussein WM; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane 4072, Australia.
  • Khalil ZG; Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland 4072, Australia.
  • Koirala P; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane 4072, Australia.
  • Capon RJ; Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland 4072, Australia.
  • Toth I; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane 4072, Australia; Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland 4072, Australia; School of Pharmacy, The University of Queensland, Brisbane 4072, Australia.
  • Stephenson RJ; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane 4072, Australia. Electronic address: r.stephenson@uq.edu.au.
Int J Pharm ; 617: 121614, 2022 Apr 05.
Article en En | MEDLINE | ID: mdl-35245637
Currently there is no approved vaccine to prevent and/or treat group A Streptococcus (GAS) infection. With increasing reports of GAS antibiotic resistance, vaccine adjuvants and targeted delivery systems which induce a strong immune response are a widely acknowledged unmet need. Through extensive structure-activity studies, we investigated a cyclic decapeptide physically mixed with a GAS B cell peptide epitope (J8), a universal T helper epitope (PADRE), and different synthetic lipidic moieties as a conceivable self-adjuvanting GAS vaccine. We explored the structure (orientation)-relationship of the chemically-conjugated B cell epitope and T helper epitope peptide as part of this physically-mixed vaccine. Following in vivo assessment in mice, these cyclic lipopeptide vaccines showed successful induction of J8-specific systemic IgG antibodies when administered subcutaneously without additional adjuvant. Interestingly, an exposed C-terminus of the GAS B cell epitope and a 16-carbon alpha-amino fatty acid lipid was required for strong immunoreactivity, capable of effectively opsonising multiple strains of clinically-isolated GAS bacteria. Physicochemical assessment proved the alpha helix structure of the GAS B cell epitope was retained, impacting particle self-assembly and vaccine immunoreactivity. This study showed the capability for a self-adjuvanting cyclic delivery system to act as a vehicle for the delivery of GAS peptide antigens to treat GAS infection.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Streptococcus pyogenes / Vacunas Límite: Animals Idioma: En Revista: Int J Pharm Año: 2022 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Streptococcus pyogenes / Vacunas Límite: Animals Idioma: En Revista: Int J Pharm Año: 2022 Tipo del documento: Article País de afiliación: Australia
...